Aurobindo Pharma’s wholly owned subsidiary Auro Vaccines has entered into a licence agreement with Hilleman Laboratories Singapore Pte. Limited to develop, manufacture and commercialise a pentavalent vaccine candidate used in children.
Auro would make milestone payments to Hilleman upon achieving certain development and clinical-study outcomes. Hilleman would also be paid royalties upon commercialisation of the vaccine candidate, Aurobindo said in a filing after trading hours on Wednesday. The Hyderabad-based parent company’s shares closed 2.61% higher at ₹880.15 each on the BSE.
Aurobindo said Auro Vaccines was not a material subsidiary and the signing of the agreement was not a material event. “It may be noted that at present entering into the licence agreement will not have any significant impact on the company and/or its subsidiaries or its financials. In the event of any significant impact in future, we will keep the exchanges informed about the same and provide necessary disclosures ,” it said.
